Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Business15 hours agoRanking the best “Magnificent Seven” stocks to buy for 2026. Here’s my No. 5 pick.
-
Noosa News14 hours agoGaming policy on council’s agenda
-
Noosa News18 hours agoInside the big change in homebuyer habits during the Christmas holidays
-
Noosa News11 hours agoJetstar flights resume across Australia after Airbus A320 software issue identified